In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mirabilis closes $10.5m in series A extension:

This article was originally published in Clinica

Executive Summary

Seattle, Washington-based Mirabilis Medica has received $10.5m in funding after it closed an extension to a series A financing round that initially took place last year. The financing, which adds to the $4m raised during the original round (see Clinica's Medtech Ventures No 1, p 2), was led by Arboretum Ventures. It also included investments from Split Rock Partners, Dow Venture Capital and an individual investor. Mirabilis is seeking funds to back the continued development and testing of its image-guided, high-intensity focused ultrasound (HIFU) system for treating gynaecological diseases.

You may also be interested in...



Goldman Sachs Gains 2 Board Seats With Burst Subscription Oral Care Investment

Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.

Health And Wellness Trademark Review 26 May, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Amivas Bests La Jolla In Race For US Approval Of Antimalarial Artesunate

La Jolla’s formulation appears blocked by Amivas’ seven-year orphan exclusivity, and the company also will miss out on chance for a tropical disease priority review voucher;  Amivas worked with the US Army to bring the severe malaria treatment through final stages of development and regulatory review.

Topics

UsernamePublicRestriction

Register

ID1129917

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel